It antagonizes the Programmed cell death protein 1 (PD-1) receptor on T-cells and the Programmed death-ligand 1 (PD-L1) protein on tumor cells leading to enhanced ability of T-cells to eliminate tumor cells and creating a robust immune response against the tumor. This evidence concerns the gene CD274 and neoplasm.